Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology

Fairfax, VA US
September 27, 2024 to September 28, 2024

Program Description

This two-day conference aimed at improving the knowledge and competence of academic and community oncology providers involved in Early Phase Clinical Trial Development and Management, Phase I/II Clinical Trials Conduct, and Management of Assessments and Safety Parameters involves more than the development of Concepts.

Recent Phase I Studies involving biomarker-guided design in the era of novel therapies has special challenges in selection of studies, patients’ enrollment along with networking with the surrounding institutions to ensure equity and inclusion of patients enrolled in the early phase studies that direct future drug development.

The activity will use a mix of didactic lectures and panel discussions to highlight various aspects of Early Phase Clinical Studies, Precision oncology, and addressing current challenges and opportunities in designing clinical trials in the era of novel therapies.

In-Person Only

This event is being offered as an in-person conference only.  There will be no virtual piece or recorded sessions.  Attendees will have the opportunity to join the speakers in-person at Inova Center for Personalized Health Conference Center (ICPH) .  

Questions & Refunds

If at any time you have questions, please email: Christina.fontana@inova.org

 

Target Audience

  • Advanced Practice Providers
  • Dietitians
  • Family Medicine
  • Genetic Counselors
  • Internists
  • Medical Oncologists
  • Nurses
  • Nurse Navigators
  • Pharmacists
  • Physicians
  • Radiation Oncologists
  • Radiologists
  • Residents, Students, and Fellows
  • Other Allied Health professionals and Trainees

Learning Objectives

  • Review challenges and trends in early drug development in the era of novel therapies.

  • Outline the best practices for the conduct of Phase I/II clinical trials in the era of novel therapies.

  • Identify phase I clinical trials to match patients’ needs.

  • Review the challenges and potential solutions for the diverse representation during drug development.


Questions about this event?  Contact Christina.fontana@inova.org

Course summary
Available credit: 
  • 16.50 AMA PRA Category 1 Credit
Course opens: 
03/01/2024
Course expires: 
12/31/2024
Event starts: 
09/27/2024 - 11:30am EDT
Event ends: 
09/28/2024 - 4:45pm EDT
Cost:
$350.00
Rating: 
0

Friday, September 27

Presentation

 

Speaker

 

Time

Registration & Networking Lunch: Trainees & Future Opportunities

Mentors: Brian Van Tine, Bassel El-Rayes, David Hong, Jaydira del Rivero, MD, Raymond Wadlow, MD

 

Trainees Organizers: Noha Soror, MD, Nina Neill, MD, Bobby Se, MD, Faran Salim Polani, MD, Ishan Patel, MD, Minira Aslanova, MD

    11:30 - 12:30 p.m.

Opening Remarks

Nagla Abdel Karim, MD

12:30 – 12:35 p.m.

Session I: Patients’ Advocates for Phase I Studies

Session Chairs: Jaydira del Rivero, MD, John Morris, MD

12:35 – 1:20 p.m.

  • Patients Story: “Patient who Went Through a Phase I Study”

Martha Wilcox (patient)

12:35 – 12:40 p.m.

  • Life with Cancer

Jennifer Bires, MD

12:40 – 12:50 p.m.

  • GO2 Foundation

Andrew Cuplick, MD

12:50 – 1:00 p.m.

  • The White Ribbon Foundation

Christ Draft, MD

1:00 – 1:10 p.m.

  • The Current Status of Cancer Survivorship

Beverly Riegle, MD

1:10 – 1:20 p.m.

Break with Exhibitors

Atrium

1:20 – 1:40 p.m.

Session II: Multidisciplinary Impact of Pharmacy and Nutrition in Phase I Programs

Session Chairs: George Maxwell, MD, Maya Khalil, MD,

1:40 – 2:40 p.m.

  • PKs: The Vital Players in Phase I Trials, Navigating Safety to Innovation

Doug Figg, PharmD

1:40 – 1:50 p.m.

  • Maximize Potential, Minimize Risk with Strategic Drug-Drug Interactions (DDI) in Phase I Trials

Safae Chouraichi, PharmD, Simona Armanca, PharmD

1:50 – 2:00 p.m.

  • Nourishing Hope: Empowering Phase I Oncology Trials Through Targeted Nutritional Support

Pamela Brandt, DO

2:00 – 2:10 p.m.

  • The Impact of Personalized Nutrition Approach in Cancer Patients

Lauren Fay, RD-AP, CSO, CNSC

2:10 - 2:20 p.m.

  • Panel Discussion

 

2:20 – 2:30 p.m.

Session III: Management of Phase I Studies

Session Chair: Teja Poosarla, MD

2:30 – 3:30 p.m.

The Unique Management of Phase I Programs

Ludimila Cavalcante, MD

2:30 – 2:40 p.m.

  • Aspirations of Current Phase I Team Members

David Hong, MD

2:40 – 2:50 p.m.

  • Study Start Up & Expedited Processes

Brian Van Tine, MD

2:50 – 3:00 p.m.

  • Optimizing Communication between Phase I team members

Margret Kamel, MD

3:00 – 3:10 p.m.

  • Panel Discussion

 

3:10 – 3:20 p.m.

Break with Exhibitors

Atrium

3:20 – 3:30 p.m.

Session IV: Revolutionizing Clinical Trials with Precision Oncology: A Game Changer in Cancer Treatment

Session Chair: Michael Pishvaian, MD, PhD

3:30 – 4:30 p.m.

  • Incorporating Targeted Therapies in Drug Development

Johnathan Ries, MD

3:30 – 3:40 p.m.

  • K-RAS Mutations in GI Oncology

Nilo Azad, MD

3:40 – 3:50 p.m.

  • Mechanisms of Resistance to K-RAS Inhibitors

Andy Aguirre, PhD

3:50 – 4:00 p.m.

  • Biomarkers in SCLC

Triparna Sen, PhD

4:00 – 4:10 p.m.

  • Panel Discussion

 

4:20 – 4:30 p.m.

  • Reception & Networking: Curate the Perfect Melody with Our Diverse Models

Atrium with music: Laith Alattar, PhD The Law Street Band (5-6 songs; 20-30 minutes),

Raymund Cuevo, MD

(Piano Session 10 minutes)

  • Fur Elise-Beethoven
  • Yesterday-The Beatles
  • Love Story-Andy Williams

4:30 – 5:30 p.m.

Session V: Evolving Landscapes from Industry

Session Chairs: Nagla Abdel Karim, MD, Ekaterine Asatiani,

5:30 – 6:30 p.m.

  • Mechanisms of Resistance ADC’s

Olivier Rixe, MD

5:30 – 5:40 p.m.

  • Equity in Early Drug Development

Leora Horn, MD; Astra Zeneca

5:40 – 5:50 p.m.

  • Panel Discussion

  Nabeel Chehab, MD, Joe Lee, MD, Exelixis, Craig Hooker, BMS

5:50 – 6:00 p.m.

    

Saturday, September 28

Presentation

 

Speaker

 

Time

 

Registration and Breakfast with Exhibitors

Atrium

7:00 – 8:00 a.m.

 

Session VI: Building Strong Foundation, Embrace Safety Excellence with Multidisciplinary Phase I Programs

Session Chairs: Germame H. Ajebo, MD, Stephen Medlin, MD

8:00 – 8:50 a.m.

 

  • Harnessing IO Toxicity Management in Phase I Studies

Elad Sharon, MD

8:00 – 8:10 a.m.

  • The Role of BiTEs in SCLC

Carl Gay, MD

8:10 – 8:20 a.m.

  • Management of Concomitant Radiation Therapy Adverse Events While Incorporating Novel Agents

Christopher Johnson, MD

8:20 – 8:30 a.m.

Panel Discussion

Question 1: CART Management Teams from Drug Development to Possible Real Time Utilization

 

Question 2: The Role of BiTEs

 

Question 3: Safety Assessment of IO/Novel Therapies and Safety Assessment of Radiation Therapy

8:30 – 8:40 a.m.

Session VII: Update on NCI-Sponsored Early Trial Program

Session Chair: Nitin Roper, MD

 

Speaker: Rabih Said, MD, MPH

8:40 – 8:50 a.m.

Session VIII: Multidisciplinary Approaches within Evolving Therapies

Session Chairs: Kei Suzuki, MD, Tim Cannon, MD

8:50 – 9:40 a.m.

  • Utilization of Novel Therapies within Neoadjuvant/Adjuvant Multidisciplinary Approaches in NSCLC

Raid Aljumaily, MD

8:50 – 9:00 a.m.

  • Redefining Possibilities: Introducing Novel Immunotherapeutic Agents Beyond Ios

Thomas Marron, MD

 

9:00 – 9:10 a.m.

  • Phase I Programs Fit within Multidisciplinary Teams

Nagla Abdel Karim, MD

9:10 – 9:20 a.m.

  • Novel Agents Exploration in MRD Positive Colorectal Cancer Post Definitive Surgery and Chemotherapy

Anwar Saeed, MD

9:20 – 9:30 a.m.

Panel Discussion

 

9:30 – 9:40 a.m.

Break with Exhibitors

Atrium

9:40 – 10:00 a.m.

Session IX: The FDA Perspective on Early Phase Studies

John Deeken, MD

10:00 – 10:40 a.m.

  • FDA

Nicole Drezner, MD

10:00 – 10:10 a.m.

  • FDA

Yufan "Frank" Liu, MD

10:10 – 10:20 a.m.

  • Pre-Market Dose Optimization

Joseph Gibbons, MD

10:20 – 10:30 a.m.

Panel Discussion

 

10:30 – 10:40 a.m.

Session X: Mastering the First Step: Essential Tools for Aspiring Clinical Investigators in Phase I Trails

 

Session Chair: Chul Kim, MD

10:40 – 11:00 a.m.

  • Early Phase Clinical Trials: Concepts, Development and Training During Fellowship

Raymond Wadlow, MD

10:40 – 10:50 a.m.

  • Panel Discussion

 

10:50 – 11:00 a.m.

Session XIV: Debate: Phase I Program as a Stand-Alone Entity vs. Distributed within Individual Disease Groups

Moderator: David Hong, MD

 

For: Rafeh Naqash, MD

Against: Asrar Al Ahmadi, MD

11:00 – 11:20 a.m.

Lunch with Exhibitors

Atrium

11:20 – 12:30 p.m.

Session XI: Navigating Complexity Phase I Programs Refined, Redefined for Optimal Results

Session Chair: Johnathan Ries, MD

12:30 – 1:45 p.m.

  • Utilization of Molecular Testing Within Phase I Programs

Stephanie Gaillard, MD

12:30 – 12:40 p.m.

  • Phase I Program at Washington University

Brian Van Tine, MD

12:40 – 12:50 p.m.

  • Discover the Key Clues to Phase I Program Model Success

Michael Pishvaian, MD, PhD

12:50 – 1:00 p.m.

  • Future of Experimental Therapeutics Program

Bassel El-Rayes, MD

1:00 – 1:10 p.m.

  • Impact of Investigator Initiated Studies on Drug Development

Vamsi Velcheti, MD, MBA, FACP, FCCP

1:10 – 1:20 p.m.

  • Panel Discussion

 

1:20 – 1:30 p.m.

Session XII: Breaking Barriers: Impact of Diversity and Specialized Care of Rare Tumors

Session Chairs: Ayham Deeb, MD, Jaydira del Rivero, Noha Soror, MD

1:30 – 2:20 p.m.

  • Increasing Diversity in Clinical Trials to Reduce Health Disparities

Estelamari Rodriguez, MD, MPH

1:30 – 1:40 p.m.

  • Collaborative Opportunities from Phase I Programs to Community Practices-Diversity Enrollment-Experience from Cooperative Group Studies

Krishna Gunturu, MD, Maya Khalil, MD

1:40 – 1:50 p.m.

  • Bridging Boundaries: Hybrid Decentralization of Phase I Trials

So Yeon Kim, MD

1:50 – 2:00 p.m.

  • The Role of Cooperative Groups in Bringing Evolving Therapies to the Next Level

Husain Hatim, MD

2:00 – 2:10 p.m.

  • Panel Discussion

 

2:10 – 2:20 p.m.

Break with Exhibitors

Atrium

2:20 – 2:40 p.m.

Session XIII: Areas of Unmet Needs to be Considered in Future Drug Development in Oncology

Session Chair: Ludi Cavalcante, MD

2:40 – 3:30 p.m.

  • Evolving Therapies in Triple Negative Breast Cancer

Teja Poosarla, MD

2:40 – 2:50 p.m.

  • Evolving Therapies in Non-Targetable NSCLC; The Treatment Desert

Johnathan Ries, MD

2:50 – 3:00 p.m.

  • Claudin 18.2. What is Next in GI Oncology Evolving Therapies?

Mathew Reilly, MD               

3:00 – 3:10 p.m.

  • Evolving Therapeutics in CNS Metastasis

Laura Alder, MD

3:10 – 3:20 p.m.

  • Evolving Therapies in Hematologic Malignancies

Aaron Goodman, MD                                                              

3:20 – 3:30 p.m.

  • Break

 

3:30 – 3:50 p.m.

Session XV: Beyond the Numbers: New Perspectives on Measurements of Success

Session Chair: Michael Winkler, MD

3:50 – 4:45 p.m.

  • Challenges incorporating Artificial Intelligence in early phase Clinical Trials

Heejong Kim, PhD

3:50 – 4:00 p.m.

Jaydira Del Rivero, MD, Hassan Hatoum, MD

4:00 – 4:10 p.m.

  • Assessment of Patients on IO Therapies

Ram Subramanian, MD

4:10 – 4:20 p.m.

  • RECIST Versus Which of the Measurements Should We Consider for Early Drug Development, Solid Tumors, NET, IO Therapies

Daniel Margolis, MD

4:20 – 4:30 p.m.

  • Panel Discussion

 

4:30 – 4:40 p.m.

  • Closing Remarks

Nagla Abdel Karim, MD

4:45 p.m.

     

 

 

Inova Center for Personalized Health Conference Center (ICPH)
8100 Innovation Park Drive
Entrance 3 - front door under Pedestrian Bridge
Fairfax, VA 22301
United States

Parking

Parking is complimentary at the Inova Center for Personalized Health Conference Center (ICPH) . Use surface lots E and F or parking garage for tower C. From the parking garage, take elevator to level 2, walk around the elevators to the bridge over to the conference center. 

Travel

Airports and Ground Transportation

Inova Center for Personalized Health Conference Center (ICPH)  is centrally located between Washington Dulles Airport (IAD) and Reagan Airports (DCA).  Union Station (in Washington, DC) is located about 30-40 minutes from the campus.  Both airports along with Union Station offer onsite ground transportation to Fairfax, VA which is about a 30–40-minute drive.  Uber or Lyft are also reliable ground transportation options in the DC metro area.

Hotels

Below are the two hotels that are located closest to the Inova Center for Personalized Health Conference Center (ICPH) and offer us discounted rates.

8296 Glass Alley, Fairfax, VA 22031

Phone: 571-327-2277

Inova/corporate rate code: 8296INOVA

 

3111 Fairview Park Dr, Falls Church, VA 22042

(703) 849-9400

    Program Director

    Nagla Abdel Karim, MD

    Director of Early Developmental Therapeutics

    Inova Schar Cancer Institute

    Professor of Medicine

    University of Virginia

     

    Advisory Committee:

    • Elad Sharon, MD
    • Rabih Said, MD, MPH

    Scientific Committee:

    • Vivek Subbiah, MD
    • Raymond Wadlow, MD
    • Teja Poosarla, MD
    • Maya Khalil

    Organizing Committee:

    • Ludimila Cavalcante, MD
    • Mathew Riley, MD

    Drug and Therapeutics Committee:

    • Safae Chouraichi, PharmD
    • Simona Armanca, PharmD

    Steering Committee:

    • Abdul Rafeh Naqash, MD
    • Ayham Deeb, MD

     

    Speaker Disclosure Statement

    Inova Health System’s Office of Continuing Medical Education adheres to ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, program directors, and planners are required to disclose all relevant financial relationships with ineligible entities as defined by ACCME.  All relevant financial relationships listed for these individuals have been mitigated.  

    Inova CME Accreditation

    The Medical Society of Virginia is a member of the Southern States CME Collaborative, an ACCME Recognized Accreditor. Inova Health System Office of Continuing Medical Education is accredited by the Southern States CME Collaborative to provide continuing medical education for physicians.

    Credit Designation

    The Inova Office of Continuing Medical Education designates this live educational activity for a maximum of 16.5 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians may claim up to 16.5 credits in Type 1 CME on the Virginia Board of Medicine Continued Competency and Assessment Form required for renewal of an active medical license in Virginia.

     

    Nurse Credentialing FAQs

    For the purpose of recertification, the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ issued by organizations accredited by the ACCME.  For more information visit,  https://www.nursingworld.org/certification/faqs/

     

    Available Credit

    • 16.50 AMA PRA Category 1 Credit

    Interested in Exhibiting? 

    General Exhibit Booth: $3,000

    • 6' undraped table with two chairs
    • Conference registration for two representatives
    • Verbal recognition the day of the conference with signage, podium mention
    • and on screen during the conference
    • Company name on:
      • Exhibitor page on event website
      • Marketing emails
      • Introduction slides, break slides, and closing slides
      • Post-event follow-up attendee email

     

    Premium Exhibitor Booth: $4,500

    • 6' undraped table with two chairs
    • Conference registration for three representatives
    • Access to sit-in on educational sessions
    • Verbal recognition the day of the conference with signage, podium mention
    • and on screen during the conference
    • Company name on:
      • Exhibitor page on event website
      • Marketing emails
      • Introduction slides, break slides, and closing slides
      • Post-event follow-up attendee email
    • Attendee registration list

     

    Nonprofit Organizations Booth - $500

    (501c3 must be submitted for approval)

    • 6' undraped table with two chairs
    • Conference registration for two representatives
    • Verbal recognition the day of the conference with signage, podium mention
    • and on screen during the conference
    • Company name on:
      • Exhibitor page on event website
      • Marketing emails
      • Introduction slides, break slides, and closing slides
      • Post-event follow-up attendee email

    Download the full prospectus here!  PDF icon <span style="color:#3498db">Evolving Therapies September 2024 PROSPECTUS FORM.pdf</span>


    Questions?  Email Christina Fontana for more information. 

     

    Price

    Cost:
    $350.00
    Please login or register to take this course.

    Registration Information:

    In order to view all the event information, please sign in or create an account.